Rituximab biosimilar (Probiomed)

利妥昔单抗生物类似药（Probiomed）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRituximab biosimilar (Probiomed)

Drug Alias Name利妥昔单抗生物仿制药（Probiomed）Rituximab (Probiomed)Rituximabum (Probiomed)KikuzubamPBO-326

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsArthritis, RheumatoidLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesProbiomed

China Registration ClassN/A

Develop Information

Active CompaniesProbiomed

Inactive CompaniesN/A

Active IndicationsArthritis, RheumatoidLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeL01XC02